Third phase III trial of ethyl eicosapentaenoic acid [LAX 101; Miraxion] in patients with Huntington's disease.

Trial Profile

Third phase III trial of ethyl eicosapentaenoic acid [LAX 101; Miraxion] in patients with Huntington's disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2009

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Huntington's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 26 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top